Patents by Inventor Marla Dubinsky

Marla Dubinsky has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNF ALPHA THERAPY IN INFLAMMATORY BOWEL DISEASE
    Publication number: 20250059605
    Abstract: The present invention relates to methods of prognosing responsiveness to anti-TNF? therapy by determining the presence or absence of risk factors in the individual. In one embodiment, the risk factors are genetic markers, serological markers and/or clinical phenotypes associated with non-responsiveness to treatment with anti-TNF? therapy in an individual diagnosed with IBD.
    Type: Application
    Filed: August 6, 2024
    Publication date: February 20, 2025
    Inventors: Jerome I. Rotter, Marla Dubinsky, Stephan R. Targan, Kent D. Taylor
  • Methods of determining responsiveness to anti-TNF? therapy in inflammatory bowel disease
    Patent number: 12084722
    Abstract: The present invention relates to methods of prognosing responsiveness to anti-TNF? therapy by determining the presence or absence of risk factors in the individual. In one embodiment, the risk factors are genetic markers, serological markers and/or clinical phenotypes associated with non-responsiveness to treatment with anti-TNF? therapy in an individual diagnosed with IBD.
    Type: Grant
    Filed: December 14, 2021
    Date of Patent: September 10, 2024
    Assignee: CEDARS-SINAI MEDICAL CENTER
    Inventors: Jerome I. Rotter, Marla Dubinsky, Stephan R. Targan, Kent D. Taylor
  • METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNF ALPHA THERAPY IN INFLAMMATORY BOWEL DISEASE
    Publication number: 20220251656
    Abstract: The present invention relates to methods of prognosing responsiveness to anti-TNF? therapy by determining the presence or absence of risk factors in the individual. In one embodiment, the risk factors are genetic markers, serological markers and/or clinical phenotypes associated with non-responsiveness to treatment with anti-TNF? therapy in an individual diagnosed with IBD.
    Type: Application
    Filed: December 14, 2021
    Publication date: August 11, 2022
    Inventors: Jerome I. Rotter, Marla Dubinsky, Stephan R. Targan, Kent D. Taylor
  • Methods of determining responsiveness to anti-TNF? therapy in inflammatory bowel disease
    Patent number: 11236393
    Abstract: The present invention relates to methods of prognosing responsiveness to anti-TNF? therapy by determining the presence or absence of risk factors in the individual. In one embodiment, the risk factors are genetic markers, serological markers and/or clinical phenotypes associated with non-responsiveness to treatment with anti-TNF? therapy in an individual diagnosed with IBD.
    Type: Grant
    Filed: July 2, 2018
    Date of Patent: February 1, 2022
    Assignee: CEDARS-SINAI MEDICAL CENTER
    Inventors: Jerome I. Rotter, Marla Dubinsky, Stephan R. Targan, Kent D. Taylor
  • METHODS OF USING SINGLE NUCLEOTIDE POLYMORPHISMS IN THE TL1A GENE TO PREDICT OR DIAGNOSE INFLAMMATORY BOWEL DISEASE
    Publication number: 20190211400
    Abstract: This invention provides methods of diagnosing or predicting susceptibility to Inflammatory Bowel Disease by determining the presence or absence of genetic variants in the TL1A gene. In one embodiment, a method of the invention is practiced by determining the presence or absence of TL1A production following Fc-gamma-R activation. In another embodiment, the invention provides methods of treatment of inflammatory bowel disease by inhibition of TL1A.
    Type: Application
    Filed: March 25, 2019
    Publication date: July 11, 2019
    Inventors: Jerome I. Rotter, Kent D. Taylor, Marla Dubinsky, Stephan R. Targan
  • METHODS OF PREDICTING COMPLICATION AND SURGERY IN CROHN'S DISEASE
    Publication number: 20190203295
    Abstract: The present invention relates to prognosing, diagnosing and treating an aggressive form of Crohn's disease characterized by rapid progression to complication and/or surgery from the time of diagnosis. In one embodiment, the prognosis, diagnosis and treatment is based upon the presence of one or more genetic risk factors.
    Type: Application
    Filed: March 15, 2019
    Publication date: July 4, 2019
    Inventors: Jerome I. Rotter, Kent D. Taylor, Marla Dubinsky, Stephan R. Targan
  • METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNF ALPHA THERAPY IN INFLAMMATORY BOWEL DISEASE
    Publication number: 20190010549
    Abstract: The present invention relates to methods of prognosing responsiveness to anti-TNF? therapy by determining the presence or absence of risk factors in the individual. In one embodiment, the risk factors are genetic markers, serological markers and/or clinical phenotypes associated with non-responsiveness to treatment with anti-TNF? therapy in an individual diagnosed with IBD.
    Type: Application
    Filed: July 2, 2018
    Publication date: January 10, 2019
    Inventors: Jerome I. Rotter, Marla Dubinsky, Stephan R. Targan, Kent D. Taylor
  • METHODS OF USING SINGLE NUCLEOTIDE POLYMORPHISMS IN THE TL1A GENE TO PREDICT OR DIAGNOSE INFLAMMATORY BOWEL DISEASE
    Publication number: 20170166967
    Abstract: This invention provides methods of diagnosing or predicting susceptibility to Inflammatory Bowel Disease by determining the presence or absence of genetic variants in the TL1A gene. In one embodiment, a method of the invention is practiced by determining the presence or absence of TL1A production following Fc-gamma-R activation. In another embodiment, the invention provides methods of treatment of inflammatory bowel disease by inhibition of TL1A.
    Type: Application
    Filed: August 24, 2016
    Publication date: June 15, 2017
    Applicant: Cedars-Sinai Medical Center
    Inventors: Jerome I. Rotter, Kent D. Taylor, Marla Dubinsky, Stephan R. Targan
  • METHODS OF PREDICTING THIOPURINE RESPONSE
    Publication number: 20120190698
    Abstract: The present invention relates to methods of predicting therapeutic efficacy of thiopurines in an individual by determining the presence of one or more risk variants. In one embodiment, the effective therapeutic efficacy of thiopurines is determined by the presence of risk variants at the genetic loci of HLA-DRB1, CREM, TAGAP, PLCL1, GPX4, SBNO2, MEF2A and/or LYSMD4. In another embodiment, the risk variants are located at the genetic loci of ARL4C, IL1R2, JAK2, 19q13, CARD9, SNAPC4, and/or 8q24. In another embodiment, the individual is has been diagnosed with inflammatory bowel disease.
    Type: Application
    Filed: January 25, 2012
    Publication date: July 26, 2012
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventors: Marla Dubinsky, Dermot P. McGovern
  • METHODS OF PREDICTING COMPLICATION AND SURGERY IN CROHN'S DISEASE
    Publication number: 20120073585
    Abstract: The present invention relates to prognosing, diagnosing and treating an aggressive form of Crohn's disease characterized by rapid progression to complication and/or surgery from the time of diagnosis. In one embodiment, the prognosis, diagnosis and treatment is based upon the presence of one or more genetic risk factors.
    Type: Application
    Filed: April 8, 2010
    Publication date: March 29, 2012
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventors: Jerome I. Rotter, Kent D. Taylor, Marla Dubinsky, Stephan R. Targan
  • METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNF ALPHA THERAPY IN INFLAMMATORY BOWEL DISEASE
    Publication number: 20110229471
    Abstract: The present invention relates to methods of prognosing responsiveness to anti-TNF? therapy by determining the presence or absence of risk factors in the individual. In one embodiment, the risk factors are genetic markers, serological markers and/or clinical phenotypes associated with non-responsiveness to treatment with anti-TNF? therapy in an individual diagnosed with IBD.
    Type: Application
    Filed: November 25, 2009
    Publication date: September 22, 2011
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventors: Jerome I. Rotter, Marla Dubinsky, Stephan R. Targan, Kent D. Taylor
  • METHODS OF USING SINGLE NUCLEOTIDE POLYMORPHISMS IN THE TL1A GENE TO PREDICT OR DIAGNOSE INFLAMMATORY BOWEL DISEASE
    Publication number: 20100190162
    Abstract: This invention provides methods of diagnosing or predicting susceptibility to Inflammatory Bowel Disease by determining the presence or absence of genetic variants in the TL1A gene. In one embodiment, a method of the invention is practiced by determining the presence or absence of TL1A production following Fc-gamma-R activation. In another embodiment, the invention provides methods of treatment of inflammatory bowel disease by inhibition of TL1A.
    Type: Application
    Filed: February 26, 2008
    Publication date: July 29, 2010
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventors: Jerome I. Rotter, Kent D. Taylor, Marla Dubinsky, Stephan R. Targan
  • DIAGNOSIS OF INFLAMMATORY BOWEL DISEASE IN CHILDREN
    Publication number: 20100015156
    Abstract: This invention provides methods of diagnosing and predicting disease progression of Crohn's disease. In one embodiment, a method of the invention is practiced by determining the presence or absence of CARD15 variants R702W, G908R, and/or 1007insC in a pediatric individual.
    Type: Application
    Filed: March 6, 2008
    Publication date: January 21, 2010
    Applicant: CEDARS-SINAI MEDICAL CENTER
    Inventors: Marla Dubinsky, Stephan R. Targan, Jerome I. Rotter